Novo Nordisk
-
Communications & Technology
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular…
Read More » -
Uncategorized
Novo Nordisk partners with Saudi Heart Association to improve cardiovascular health in Saudi Arabia
Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi Heart…
Read More »